398 related articles for article (PubMed ID: 35008368)
1. Emerging Biomarkers in Thyroid Practice and Research.
Agarwal S; Bychkov A; Jung CK
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008368
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
Dell'Aquila M; Granitto A; Martini M; Capodimonti S; Cocomazzi A; Musarra T; Fiorentino V; Pontecorvi A; Lombardi CP; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
Cancer Cytopathol; 2020 Mar; 128(3):177-189. PubMed ID: 31821747
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Biomarkers in Thyroid Pathology.
Baloch Z; Mete O; Asa SL
Endocr Pathol; 2018 Jun; 29(2):91-112. PubMed ID: 29744727
[TBL] [Abstract][Full Text] [Related]
4. Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer.
Romano C; Martorana F; Pennisi MS; Stella S; Massimino M; Tirrò E; Vitale SR; Di Gregorio S; Puma A; Tomarchio C; Manzella L
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299334
[TBL] [Abstract][Full Text] [Related]
5. Potential of Liquid Biopsy in Papillary Thyroid Carcinoma in Context of miRNA, BRAF and p53 Mutation.
Perdas E; Stawski R; Nowak D; Zubrzycka M
Curr Drug Targets; 2018; 19(14):1721-1729. PubMed ID: 29484992
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modifications in human thyroid cancer.
Faam B; Ghaffari MA; Ghadiri A; Azizi F
Biomed Rep; 2015 Jan; 3(1):3-8. PubMed ID: 25469237
[TBL] [Abstract][Full Text] [Related]
7. Novel Molecular Markers in Glioblastoma-Benefits of Liquid Biopsy.
Birkó Z; Nagy B; Klekner Á; Virga J
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053907
[No Abstract] [Full Text] [Related]
8. Non-Coding RNAs: Uncharted Mediators of Thyroid Cancer Pathogenesis.
Tabatabaeian H; Peiling Yang S; Tay Y
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33158279
[TBL] [Abstract][Full Text] [Related]
9. In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related.
Bai Y; Guo T; Huang X; Wu Q; Niu D; Ji X; Feng Q; Li Z; Kakudo K
Virchows Arch; 2018 May; 472(5):779-787. PubMed ID: 29651624
[TBL] [Abstract][Full Text] [Related]
10. Role of tissue and circulating microRNAs and DNA as biomarkers in medullary thyroid cancer.
Chiacchiarini M; Trocchianesi S; Besharat ZM; Po A; Ferretti E
Pharmacol Ther; 2021 Mar; 219():107708. PubMed ID: 33091426
[TBL] [Abstract][Full Text] [Related]
11. Update on Fundamental Mechanisms of Thyroid Cancer.
Prete A; Borges de Souza P; Censi S; Muzza M; Nucci N; Sponziello M
Front Endocrinol (Lausanne); 2020; 11():102. PubMed ID: 32231639
[TBL] [Abstract][Full Text] [Related]
12. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Vesicles from Thyroid Carcinoma: The New Frontier of Liquid Biopsy.
Rappa G; Puglisi C; Santos MF; Forte S; Memeo L; Lorico A
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30841521
[TBL] [Abstract][Full Text] [Related]
14. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
15. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
16. Potential of epigenetic events in human thyroid cancer.
Ahmed AA; Essa MEA
Cancer Genet; 2019 Nov; 239():13-21. PubMed ID: 31472323
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases.
Insilla AC; Proietti A; Borrelli N; Macerola E; Niccoli C; Vitti P; Miccoli P; Basolo F
Oncol Lett; 2018 Mar; 15(3):2763-2770. PubMed ID: 29435002
[TBL] [Abstract][Full Text] [Related]
18. Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer.
Zane M; Agostini M; Enzo MV; Casal Ide E; Del Bianco P; Torresan F; Merante Boschin I; Pennelli G; Saccani A; Rubello D; Nitti D; Pelizzo MR
Biomed Pharmacother; 2013 Oct; 67(8):723-30. PubMed ID: 23931930
[TBL] [Abstract][Full Text] [Related]
19. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
20. Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules.
Ye W; Hannigan B; Zalles S; Mehrotra M; Barkoh BA; Williams MD; Cabanillas ME; Edeiken-Monroe B; Hu P; Duose D; Wistuba II; Medeiros LJ; Stewart J; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2019 Mar; 127(3):146-160. PubMed ID: 30620446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
